Vulnerable patient populations have seen decreased rates of vaccination against SARS-CoV2 (COVID-19) due to hesitancies and distrust, magnified by a paucity of data for certain populations. The rates of COVID-19 vaccination in children with Sickle Cell Disease (SCD) remains low despite the risk for severe complications, resulting in continued infections and hospitalizations from COVID-19. We sought to describe vaccine reactions including vaso-occlusive crises, emergency department visits, and hospitalizations in children with SCD. Our findings will start to provide the necessary vaccine side effect data to inform patients, caregivers, and clinicians considering the COVID-19 primary vaccination series.